AML and MDS - A Review of the ViALIA Trial

Richard Stone: I'm the Chief of Staff at Dana-Farber Cancer Institute. The ViALIA trial was published by Courtney Denardo with a newinlageal in medicine two years ago. Comparing the then standard of care for older adults with AML as a side in to what turned out to be the new standard of care, which is an enetoclax and BCL2 inhibitor.